New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
- Details
- Category: Novartis
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1].
Landmark outcomes study shows that Repatha® (Evolocumab) decreases LDL-C to unprecedented low levels and reduces risk of cardiovascular events
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the 27,564-patient Repatha® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations.
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
- Details
- Category: AstraZeneca
AstraZeneca today announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for the development and commercialisation of Tudorza and Duaklir* in the US. Tudorza and Duaklir are inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease (COPD).
Johnson & Johnson reports that investigational Ebola vaccine regimen induced durable immune response 1 year after vaccination in Phase 1 study
- Details
- Category: Johnson & Johnson
Johnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: The Journal of the American Medical Association show that Janssen Pharmaceutical Companies' investigational "prime-boost" Ebola vaccine regimen induced a durable immune response in 100 percent of healthy volunteers one year following vaccination.
LEO Innovation Lab CEO wins eyeforpharma Customer Innovator Award
- Details
- Category: Business
LEO Innovation Lab is proud to announce that our CEO Kristian Hart-Hansen has won the eyeforpharma Customer Innovator Award. Kristian has spearheaded the growth of the LEO Innovation Lab since it's conception in 2015 with just six team members, to a thriving incubator of over 80 people and 15 projects today. The lab was established by LEO Pharma as an independent initiative to focus on using digital innovation to help individuals manage chronic skin conditions.
Roche Annual General Meeting 2017
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). The 855 attending shareholders, representing 86.3% of the total of 160,000,000 shares, approved the Annual Report, the Financial Statements and the Consolidated Financial Statements for 2016.
Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
- Details
- Category: Novartis
Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel of judges at the Wired Health 2017 event in London, identified innovative approaches to address challenges in Ghana, the Maldives and the Philippines. The winning ideas all proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines, addressing access issues specific to their country but with the potential for solutions to be applied elsewhere.
More Pharma News ...
- The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients
- Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers
- MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
- Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
- Phase III APHINITY study shows Roche's Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy
- Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL
- Johnson & Johnson completes acquisition of Abbott Medical Optics